Breaking News

Trials & Filings in Brief: Oct. 31, 2013

By Gil Roth | October 31, 2013

Ariad, Baxter, e-Therapeutics, Hyperion, Kamada, Mesoblast, Stem Cell Therapeutics, Teva

Phase I
Kamada reports preliminary pediatric diabetes data . . . read more

Phase II
e-Therapeutics starts trial of tramadol CR formulation . . . read more

Phase III
Teva gets approval for CHF trial . . . read more

Post-Approval
Hyperion begins UCD outcomes study . . . read more

Filings
Ariad suspends Iclusig marketing in U.S. . . . read more

Baxter submits Rixubis in EU . . . read more

Stem Cell Therapeutics gets Orphan status for tigecycline in AML . . . read more
  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials